The Canadian Cancer Research Alliance (CCRA) today announced that Dr. John Bell, BioCanRx’s Scientific Director, will receive the award for Outstanding Achievements in Cancer Research for his pioneering work and ground-breaking scientific discoveries, which have propelled the entire field of oncolytic virus therapy forward, and his commitment to enabling translational research. The award is… Read more »
Category: News
Dr. John Bell speaks to CBC News about the FDA approval of a second CAR-T cell therapy
New immunotherapy drug approved, but not in Canada By: CBC News – Second Opinion Headlines this week announcing the approval of a new immunotherapy treatment might be raising expectations of cancer patients everywhere. But unfortunately for most patients right now, nothing will change. The new treatment by Gilead, called Yescarta, is the second… Read more »
Developing Cancer Research Communication Skills: Q & A with Candice Tang a Master’s student in Applied Immunology
Master’s student Candice Tang has the unique opportunity to develop her research communications skills with an internship at the Canadian Cancer Society. This joint partnership is funded by BioCanRx under our training program. The internship was created to enable a graduate student from the cancer research community to gain communication experience within a prominent cancer… Read more »
From heartbreak to hope
by: Heather Blumenthal Being a pediatric oncologist can be heartbreaking. But every so often a glimmer of hope arises – often from the most unexpected places. Dr. Uri Tabori, an oncologist at Toronto’s Hospital for Sick Children, together with several physicians and scientists, is leading a unique international consortium that helps treat children’s… Read more »
Cancer-fighting Ottawa startup Turnstone Biologics signs licensing agreement
By: Ottawa Business Journal An Ottawa biotech startup that is developing groundbreaking cancer-fighting viruses has inked a deal with a U.S. biopharmaceutical firm to market and sell its products. Under the agreement announced this week, Illinois-based AbbVie will have the exclusive right to license up to three of Turnstone Biologics’ immunotherapy treatments for… Read more »
Turnstone Biologics named one of FierceBiotech’s 2017 Fierce 15
“Congratulations to Turnstone Biologics – named one of FierceBiotech’s Fierce 15! A true Canadian biotech success story! BioCanRx is proud to have Turnstone as our partner in bringing immunotherapy to cancer patients,” – Stéphanie Michaud, President & CEO, BioCanRx. Fierce Biotech’s 2017 Fierce 15 The philosophy of Fierce 15 is a simple one: We want to… Read more »
New treatment approaches for a stubborn cancer
by: Heather Blumenthal Throughout the world, ovarian cancer researchers using mouse models to further their research on the origins, development or treatment of the cancer can thank Ottawa researcher Dr. Barbara Vanderhyden for making their research possible. An ovarian cancer researcher for more than a quarter century, and currently the inaugural holder of… Read more »
The Learning Institute Pilot – Testimonials From Participants
The BioCanRx-Cancer Stakeholder Alliance Learning Institute debuted at this year’s Summit for Cancer Immunotherapy. The pilot model was developed and organized by members of the Cancer Stakeholder Alliance Working Group and our HQP community. It brought together patient/public leaders and academic scholars in an interactive and collaborative knowledge exchange program. We asked two of the participants, a… Read more »
Meet Two of BioCanRx’s Summer Students
As summer comes to an end, so does a BioCanRx-funded 14-week research internship in cancer immunotherapeutics for 15 bright and enthusiastic undergraduate students. We are incredibly proud of the learning and development our summer students achieved and wish them all the best in their future endeavours. Here’s a taste of what two students were… Read more »
Dr. John Bell speaks to CBC News on how BioCanRx researchers are working out a made-in-Canada CAR-T cell therapy protocol
By: CBC News U.S. approves genetically engineering blood cells as childhood leukemia treatment In Canada, scientists working on protocol that is affordable for the public health-care system Opening a new era in cancer care, the U.S. Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients’ own blood cells into… Read more »
